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The efficacy of sodium diethyldithiocarbamate (DDTC), S-
2(3-aminopropylamino)ethylphosphorothioic acid (WR-2721) and
sodium selenite in reducing the toxicity of the second-
generation platinum compound tetrachloro(d,1-trans)1,2-
diaminocyclohexaneplatinum(IV) (tetraplatin) was investigated.
These three chemoprotectors were chosen based on their ability
to reduce cisplatin toxicity. The dose-limiting factors with
tetraplatin administration are myelosuppression,
gastrointestinal toxicity and nephrotoxicity. In the toxicity
studies DDTC and WR-2721 were effective in reducing
nephrotoxicity and gastrointestinal toxicity (as measured by
blood urea nitrogen, creatinine and histopathological
examination), but only DDTC was able to reduce the
myelosuppressive effects of tetraplatin (as measured by white
blood cells, platelets, lymphocytes and histopathological
examination). Sodium selenite was ineffective in protecting
against any of the tetraplatin-associated toxicities.
Subsequent to the toxicity studies, tetraplatin
pharmacokinetic and biotransformation product studies in the
presence of DDTC were performed. When tetraplatin was
administered alone, 90% of the platinum in plasma was protein-
bound after 3 hr and approximately nine different
biotransformation products were detected by reverse phase and
cation exchange HPLC. This group of biotransformation products
included a monoaguamonochloro species, trans-1,2-
diaminocyclohexanedichloroplatinum(II) (PtCl2(trans-dach)), a
mixture of methionine-platinum complexes, free trans-1,2-
diaminocyclohexane (trans-dach) and unmetabolized tetraplatin.
DDTC administered at 0.5 hr after tetraplatin injection
resulted in significant changes in the platinum pharmacokinetic
profiles and the tetraplatin biotransformation products. Only
60% of the platinum was protein-bound 3 hr after tetraplatin
administration (2.5 hr after DDTC) resulting in a substantial
increase in free platinum. Additionally, the free trans-dach
dramatically increased after DDTC administration, while the
methionine-platinum complexes were eliminated and the
PtCl2(trans-dach) and the monoaguamonochloro species decreased
by a factor of 2. These data suggest that the DDTC was
displacing the trans-dach moiety from protein-bound platinum by
formation of a bis, bidentate platinum(II)-DDTC complex.
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CHAPTER I
INTRODUCTION TO PLATINUM ANTICANCER COMPOUNDS
AND CHEMOPROTECTIVE COMPOUNDS
cis-Diamminedichloroplatinum(II) (cisplatin) (Figure 1) is
used frequently in cancer chemotherapy and is particularly
effective against testicular and ovarian cancers (Rosenburg,
1985). Cisplatin is very reactive and has been found to form a
number of different platinum-DNA adducts (Figure 2). Recent
studies suggest that it exerts its anticancer effect by forming
DNA intrastrand crosslinks in replicating cancer cells
(Eastman, 1987). In addition to its reactivity with malignant
cells, cisplatin also reacts to some extent with DNA and
proteins of normal tissues. Consequently, the dose-limiting
factor with cisplatin treatment is nephrotoxicity, which can be
reduced to some extent with proper hydration (Walker and Gale,
1981). Other toxic side effects associated with cisplatin
include myelosuppression, gastrointestinal toxicity,
ototoxicity and neurotoxicity (Walker and Gale, 1981;
Rosenburg, 1985).
Because of these toxicities and acquired cisplatin
resistance in human tumors, other platinum species have been
developed. Tetrachloro(d,l-trans)1,2-diaminocyclohexane-
platinum(IV) (tetraplatin) (Figure 1) is a second-generation
platinum compound recently approved for phase I/II clinical
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Figure 1.  Structural Formula of Cisplatin and Tetraplatin
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Figure 2.  Types of Platinum-DNA Adducts Formed by
Ciplatin
trials (Anderson et al., 1986). Tetraplatin is of potential
clinical significance because of its reduced nephrotoxicity (as
measured by renal enzymes and histology) in animal models
(Smith et al., 1988) and its efficacy in cisplatin-resistant
cell lines (Anderson et al., 1986; Wilkoff et al., 1987).
Recent studies in Fischer 344 rats suggest that
myelosuppression and gastrointestinal toxicity are dose-
limiting with tetraplatin administration (Smith et al., 1988),
Various chemical agents have been employed in an attempt
to reduce the dose-limiting side effects associated with
cisplatin treatment. To date, a number of these protective
agents appear to be effective in reducing the toxicity
associated with cisplatin when administered prior to or
following cisplatin injection. Included in this group of
potential chemoprotectors are sodium diethyldithiocarbamate
(DDTC), S-2(3-aminopropylamino)ethylphosphorothioic acid (WR-
2721) and sodium selenite (Figure 3).
DDTC has been the most extensively studied of this group
of chemoprotectors. DDTC has been found to decrease the
nephrotoxic and myelosuppressive effects of cisplatin in the
rat model when administered 0.5 to 4 hr following cisplatin
injection (Borch and Pleasants, 1979) without affecting its
therapeutic effectiveness against the subcutaneously implanted
rat mammary tumor 13762 (Borch et al., 1980). It has also
proven effective in ameliorating cisplatin-associated
toxicities in phase I clinical trials (Qazi et al., 1988;
Gandara et al., 1989). Although a mechanism of action is not
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Figure 3.  Structural Formulas for DDTC, WR-2721 and Sodium
Selenite
clearly defined at this point for DDTC, Borch and coworkers
have deduced several theories. Based on its in vitro reactivity
and in vivo concentrations, DDTC was not believed to interact
with cisplatin at physiological concentrations found in blood
(Dedon and Borch, 1987). It has been postulated that DDTC may
reverse the platinum inactivation of renal proximal tubule
enzymes (Dedon and Borch, 1987) or may have a stimulatory
effect on bone marrow (Gringeri et al., 1988). DDTC appears to
have the most promise of the chemoprotective agents once dosing
and timing are optimized in phase I trials.
WR-2721 (Yuhas and Culo, 1980) has been proven effective
in reducing cisplatin toxicity in animal models when
administered 0.5 hr prior to cisplatin injection. This
sulfhydryl compound has also been found effective in reducing
cisplatin toxicity in phase I trials (Glover et al., 1986;
Mollman et al., 1988). WR-2721 is believed to exert its
protective effect via rapid uptake by normal tissue while
absorption by solid tumors is minimal (Yuhas, 1980). Calabero-
Jones et al. (1988) have demonstrated that the sulfhydryl form
of the drug (WR-1065) is the species absorbed by normal tissues
and possibly responsible for its protective effect. This group
has also proposed that the conversion of WR-2721 to WR-1065
occurs by selective dephosphorylation at or near the membrane
surface of normal tissues.
Protection against cisplatin toxicity by sodium selenite
is limited to studies in animal models. Sodium selenite has
been found effective when administered 4 hr prior to
administering cisplatin (Berry et al., 1984). Far fewer studies
have been performed with sodium selenite in regard to mechanism
of action. Ohkawa and coworkers (1988) have suggested the
protective mechanism of involves the formation of a metal-
selenium complex, thus clearing the toxic platinum metabolites
from the circulation.
Pharmacokinetic parameters for cisplatin have been defined
both in animal models and in humans (Dominici et al., 1989;
Rahman et al., 1988). In the study by Rahman et al., (1988), it
was determined that the difference between tetraplatin and
cisplatin pharmacokinetics was the ^1/2     ^^^  ^l/2B values. The
^1/2  ^^^ ^1/26 values for free (unbound) platinum in
tetraplatin-treated rats were 10.9 min and 7.47 hr,
respectively, while in cisplatin-treated rats they were 13.1
min and 13.09 hr, respectively. All other pharmacokinetic
parameters (AUC, Vj^, V^g and clearance) were similar for the
two drugs. It has also been suggested that tetraplatin binds
more strongly to plasma proteins than does cisplatin (Rahman et
al., 1984) .
Metabolic products of cisplatin have also been described
in the rat model by Daley-Yates and McBrien (1984). These
investigators were able to characterize tentatively a
methionine-platinum complex and a number of aquated species. In
studying tetraplatin biotransformation, Chaney and coworkers
(Gibbons et al., 1989; Mauldin et al., 1988) have been able to
describe a number of putative metabolites in RPMI 1640 tissue
culture medium and the L1210 cell line. Included in this group
of metabolites are a methionine complex, a monoaquamonochloro
species, d,l-trans-l,2-diaminocyclohexane (trans-dach) and d,l-
trans-l,2-diaminocyclohexanedichloroplatinum(II) (PtCl2(trans-
dach) ) . The PtClj(trans-dach) is a platinum(II) analog which
has been found to be the reduction product of tetraplatin
(Gibbons et al., 1989). Their data suggest that the protein
sulfhydryl groups in serum are responsible for the rapid
reduction of tetraplatin to PtCl2(trans-dach).
Based on these preclinical and clinical trials with DDTC,
WR-2721 and sodium selenite, this study was designed to
determine the effects of these chemoprotectors on the
toxicities associated with tetraplatin treatment, and to
elucidate a possible mechanism of action for the chemoprotector
which proved most effective in reducing tetraplatin toxicity.
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CHAPTER II
PROTECTIVE EFFECTS OF DIETHYLDITHIOCARBMATE, S-2(3-
AMINOPROPYLAMINO)ETHYLPHOSPHOROTHIOIC ACID AND SODIUM SELENITE
ON TETRACHLORO(d,l-trans)1,2-DIAMIN0CYCL0HEXANEPLATINUM(IV)
TOXICITY
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Introduction
These initial experiments were used to determine which of
the protective agents are most effective in reducing
tetraplatin toxicity. Others have found that DDTC, WR-2721 and
sodium selenite can effectively reduce cisplatin toxicity
(Borch and Pleasants, 1979; Yuhas and Culo, 1980; Berry et al.,
1984). Smith et al. (1988) have determined that cisplatin is
more nephrotoxic than tetraplatin, and that the dose-limiting
factors with tetraplatin treatment are myelosuppession and
gastrointestinal toxicity. BUN, creatinine, neutrophils +
monocytes, lymphocytes, WBC, platelets and histopathological
damage were measured to determine which chemoprotector was most
effective.
Materials and Methods
A. Reagents
Tetrachloro(d,1-trans)1,2-diaminocyclohexaneplatinum(IV)
(tetraplatin) was kindly supplied by Dr. Steven D. Wyrick
(Department of Medicinal Chemistry, University of North
Carolina, Chapel Hill, NC). The synthesis of this compound has
been described previously (Wyrick and Chaney, 1988). Sodium
diethyldithiocarbamate (DDTC) and sodium selenite (NaSe) were
obtained from Sigma Chemical Co (St. Louis, MO). S-2-(3-
Aminopropylamino)ethylphosphorothioic acid (WR-2721) was a gift
from the Drug Synthesis and Chemistry Branch, Division of
Cancer Treatment, National Cancer Institute, Bethesda, MD. All
compounds were dissolved in 0.15 M NaCl (saline) immediately
14
prior to injection. To assure dissolution, tetraplatin was
heated at 60°C for 1 hr in a shaker bath. All other reagents
were purchased from commercial sources and were reagent grade
or better.
B. Animals and Dosing Schedule
Adult male Fischer 344 rats were obtained from Charles
River Breeding Laboratories, Raleigh, NC. The rats weighed 170-
250 g and were housed on a 12-hr light/dark cycle in stainless
steel cages with room temperature maintained at 22°C. The
animals were allowed Purina rodent chow and water ad libitum.
At least a 3-day acclimation period was allowed prior to
injection of drug or vehicle. Tetraplatin or an equivalent
volume of vehicle (0.15 M NaCl) were administered in a single
iv (tail vein) injection under light ether anesthesia. Four
doses of tetraplatin were used: 12, 15, 16.5 and 18 mg/kg of
body weight. For the 12 and 16.5 mg/kg doses, DDTC was
administered ip following the tetraplatin  injection. WR-2721
or sodium selenite was administered ip preceding the 16.5 mg/kg
tetraplatin dose. The timing of these compounds was as follows:
750 mg/kg DDTC 0.5 hr after, 750 or 500 mg/kg DDTC 2 hr after,
200 mg/kg WR-2721 0.5 hr before, or 0.5, 1.0 or 2.0 mg/kg NaSe
4 hr before tetraplatin injection. Usually 9 or 10 animals were
treated at a time with three receiving vehicle, three receiving
tetraplatin alone and three or four receiving tetraplatin plus
DDTC, WR-2721 or NaSe. Those animals receiving tetraplatin, but
not treated with DDTC, WR-2721 or NaSe were administered an
equivalent volume of vehicle ip. Other groups of animals were
15
administered DDTC, WR-2721 or NaSe alone to determine if the
chemoprotectors alone had any adverse effects.
C. Biochemical plasma indices and hematology.
Blood was collected in heparinized centrifuge tubes on day
3 and day 5 after tetraplatin injection. All animals were
anesthetized with Ketamine/Rompun (25 and 5 mg/kg,
respectively) prior to bleeding. Diagnostic kits from Sigma
Chemical Co. were used to determine urea nitrogen (BUN) and
creatinine in plasma. White blood cell counts (WBC) were
performed on whole blood (1:20 dilution in 2% glacial acetic
acid) with a Bright-Line Neubauer 1/10 mm hemacytometer.
Differential cell counts and platelets were determined from
whole blood by the peroxidase method (Saunders et al., 1971)
with a Technicon H*l flow cytometer equipped with a tungsten
light source and laser.
D. Histology
Rats were killed on day 5 after tetraplatin injection by
exsanguination. Representative tissue samples of the kidney,
thymus, spleen, stomach, large intestine and small intestine
were obtained from each group of rats. Tissues were washed with
0.15 M NaCl, fixed in 10% buffered formalin, and paraffin
sections were stained with hematoxylin and eosin. The histology
slides were prepared and interpreted by Dr. J. Chang, Division
of Laboratory Animal Medicine and the Department of Pathology,
University of North Carolina, Chapel Hill, NC.
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E. Statistical analysis.
Groups were compared by Student's t-test with a standard
statistical software program (SYSTAT).
Results
Based on previously published results (Smith et al.,
1988a), 12 mg/kg of tetraplatin was selected as the toxic dose.
Preliminary experiments showed that 750 mg/kg DDTC was more
effective than 500 mg/kg and that DDTC was more effective if
administered 0.5 hr rather than 2 hr after tetraplatin (Table
1). Toxicity studies were initiated with 12 mg/kg tetraplatin
and, in some cases, 750 mg/kg DDTC was administered 0.5 hr
later (Table 2). Excellent protection was provided as
determined by all the parameters measured on days 3 and 5 when
DDTC was used. However, the response of the animals to
tetraplatin was variable. At a 12 mg/kg dose, 50% of the
animals showed little or no elevation in BUN and creatinine
values. This resulted in large standard errors for the BUN and
creatinine values. A dose-response experiment was designed to
determine the optimal tetraplatin dose (Table 3). At 18 mg/kg,
a large number of deaths occurred, while at 15 mg/kg, the
response was still quite variable. Based on these experimental
data, a dose of 16.5 mg/kg was used.
In studies described by Berry et al. (1984), sodium
selenium was most effective at reducing cisplatin toxicity at
doses just below the threshold of toxicity for selenium alone.
Thus, the effects of sodium selenite alone at three different
17
TABLE!
Determination of Optimal DDTC Dose and Timing
in the Fischer 344 Rat
BUN^   Creatinine^      WBC^   .
Treatment    N   (mg/dl)    (mg/dl)   (cells/ml) x 10"
Day 3
12 mg/kg TP +    3 61.7 ±32.2 4.74 ± 3.38    3.3 ±1.4
500 mg/kg DDTC*
12 mg/kg TP +   4 45.3 ± 23.8 0.99 ± 0.32    2.7 ± 0.2
750 mg/kg DDTC*
12 mg/kg TP +    3 17.7 ± 2.6  0.67 ± 0.07    3.3 ± 0.3
750 mg/kg DDTC**
Day 5
12 mg/kg TP +    3 95.0 ± 63.8 6.24 ± 3.02    2.6 ± 1.1
500 mg/kg DDTC*
12 mg/kg TP +   4 38.0 ± 19.4 0.58 ± 0.37    3.0 ± 0.4
750 mg/kg DDTC*
12 mg/kg TP +    3 14.7 ± 0.3  0.44 ± 0.03    3.2 ± 0.1
750 mg/kg DDTC**
Mean ± standard error. BUN, creatinine and WBC were measured as
described in Materials and Methods.
*Animals treated with DDTC 2 hr after tetraplatin.
**Animals treated with DDTC 0.5 hr after tetraplatin.
TABLE 2
Effect of DDTC on Plasma Parameters
in the Fischer 344 Rats Treated with Tetraplatin
BUN^     Creatinine"^        WBC^    .
Treatment   N    (mg/dl)      (mg/dl)    (cells/ml) x 10"
Vehicle       21  18.4 ± 0.6   0.56 ± 0.05      4.9 ± 0.1
Day 3
12 mg/kg TP    19 34.8 ± 5.4*  1.13 ±0.21*     2.0 ±0.2*
12 mg/kg TP +  7  17.4 ±1.8** 0.68 ± 0.04***   3.1 ± 0.1**
750 mg/kg DDTC
Day 5
12 mg/kg TP   17 58.0 ± 14.5* 1.48 ±0.38*     1.8 + 0.2*
12 mg/kg TP +  7  15.2 ± 0.3** 0.413 ± 0.03***   3.2 ± 0.1**
750 mg/kg DDTC
^Animals were treated with DDTC 0.5 hr after tetraplatin. DDTC,
diethyldithiocarbamate, and TP, tetraplatin.
bMean ± standard error. BUN, creatinine and WBC were measured
as described in Materials and Methods.
*Statistically different from controls (p < 0.05).
**Statistically different from TP group (p < 0.01).
***Statistically different from TP group (p < 0.05).
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TABLE 3
Determination of the Optimal Tetraplatin Dose
in the Fischer 344 Rat
BUN^   Creatinine^ WBC
Treatment     N        (mg/dl) (mg/dl)        (cells/ml) x 10
-6
Day 3 .
12 mg/kg TP 3 23.7 ± 2.2 0.37 ±0.07 1.4 + 0.1
15 mg/kg TP 3 27.7 ± 2.0 0.89 ± 0.14 1.9 ± 0.3
13 mg/kg TP 6 64.0 ± 15.6 1.45 ±0.26 2.0 ±0.2
Day 5
12 mg/kg TP 3 23.3 ± 2.4 0.52 ± 0.12
15 mg/kg TP 3 20.3 ± 2.4 0.59 ± 0.10
18 mg/kg TP 2 69.0 ± 42.0 1.74 ±0.78
1.2 ± 0.1
1.3 ± 0.1
1.4*
Mean ± standard error. BUN, creatinine and WBC were
measured as described in Materials and Methods.
*One of the two surviving animals could not be assayed for
WBC due to lack of blood.
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doses: 0.5, 1.0 and 2.0 mg/kg were tested (Table 4). Control
experiments were also carried out for the two other protective
agents (Table 5). DDTC (750 mg/kg) or WR-2721 (200 mg/kg) alone
had only a slight effect on WBC counts and did not affect the
BUN and creatinine values. Sodium selenite alone resulted in a
modest elevation in creatinine on days 3 (2.0 and 1.0 mg/kg)
and day 5 (2.0 mg/kg).
Based on the preliminary experiments described above, 16.5
mg/kg tetraplatin was administered iv. 750 mg/kg DDTC was
administered ip at 0.5 hr after tetraplatin. Sodium selenite
was administered ip at 0.5, 1.0, or 2.0 mg/kg 4 hr before
tetraplatin using the protocol of Berry et al. (1984). WR-2721
(200 mg/kg) was administered 0.5 hr before tetraplatin using
the protocol of Yuhas and Culo (1980). Tetraplatin treatment
(16.5 mg/kg) resulted in 67% survival rate through day 5. All
saline control animals and those protected with DDTC (750
mg/kg) or WR-2721 (200 mg/kg) survived to day 5 of the study.
Rats protected with sodium selenite at doses of 0.5, 1.0 or 2.0
mg/kg showed 80, 80 and 60% 5-day survival, respectively.
Diarrhea incidence was qualitatively observed on day 5. While
no incidence of diarrhea was seen in the saline controls, DDTC-
protected or WR-2721-protected rats, diarrhea was evident in
95% of the rats receiving tetraplatin (16.5 mg/kg) alone.
Animals treated with 0.5, 1.0 or 2.0 mg/kg sodium selenite
showed 60, 80 and 80% incidence of diarrhea, respectively.
Based on BUN and creatinine values, tetraplatin-treated
animals (12 and 16.5 mg/kg) could be divided into responders
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TABLE 4
Effect of Sodium Selenite when Administered
Alone in the Fischer 344 Rat^
BUN*^   Creatinine^      WBC^   ^Treatment   N   (mg/dl)    (mg/dl)   (cells/ml) x 10"
Vehicle 21 18.4 ± 0.6 0.56 ± 0.05 4.9 ± 0.1
Day 3
0.5 mg/kg NaSe 3 20.3 ± 0.7 0.67 ± 0.05 4.7 ± 0.3
1.0 mg/kg NaSe 3 19.3 ± 0.3 0.91 ± 0.01 4.7+0.2
2.0 mg/kg NaSe 3 16.3 ±1.7 0.84 ± 0.09 4.3+0.2
Day 5
0.5 mg/kg NaSe 3 17.0 ± 2.1 0.69 ± 0.03 4.2 ± 0.8
1.0 mg/kg NaSe 3 14.7 ± 0.9 0.69 ± 0.04 3.7 ± 0.1
2.0 mg/kg NaSe 3 13.0 ±1.2 0.93 ± 0.09 4.7 ±0.7
Animals were treated with NaSe (sodium selenite) only.
Mean ± standard error, BUN, creatinine and WBC were measured
as described in Materials and Methods.
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TABLE 5
Effect of DDTC and WR-2721 when Administered Alone on
Plasma Parameters in the Fischer 344 Rat^
BUN*^    Creatinine*^       WBC*^    .
Treatment    N   (mg/dl)    (mg/dl)   (cells/ml) x 10~°
21  18.4 ± 0.6 0.56 ± 0.05 4.9 ± 0.1
18.2 ± 0.9 0.70 ± 0.05 4.5 ± 0.1*
20.2 ± 0.6 0.68 ± 0.03 3.9 ± 0.1*
18.1 ± 1.1 0.64 ± 0.06 4.6 ± 0.3
19.2 ± 0.9 0.55 ± 0.8 3.9 ± 0.3*
Animals were treated with DDTC  (diethyldithiocarbamate)  or
WR-2721   (S-2(3-aminopropylamino)ethylphosphorothioic acid) only.
Mean ± standard error.    BUN, creatinine and WBC were measured
as described in Materials and Methods.
*Statistically different from controls  (p < 0.01).
Vehicle
Day 3
750 mg/kg DDTC 7
200 mg/kg WR-2721 7
Day 5
750 mg/kg DDTC 7
200 mg/kg WR-2721 7
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and non-responders. In most of the animals treated with
tetraplatin, both BUN and creatinine values increased
significantly. However, approximately 50% (12 mg/kg) and 25%
(16.5 mg/kg) of the animals showed little or no elevation in
BUN or creatinine. This differential response did not appear to
be due to a problem with injection since all of the treated
animals showed a similar decrease in WBC and other parameters
tested. The data in Tables 2, 6, and 7 include both responders
and non-responders.
For all tetraplatin-treated animals (16.5 mg/kg), DDTC
rescue (750 mg/kg) and WR-2721 pretreatment (200 mg/kg) had a
profound influence on plasma BUN and creatinine concentrations
on days 3 and 5. DDTC and WR-2721 protection resulted in a
significant decrease in mean BUN and creatinine values on days
3 and 5 when compared to animals receiving tetraplatin (16.5
mg/kg) only (Table 6). On days 3 and 5, BUN and creatinine
levels approximated controls for DDTC- and WR-2721-treated
animals. Pretreatment with 0.5, 1.0 or 2.0 mg/kg sodium
selenite was ineffective in reducing BUN and creatinine levels.
In tetraplatin-treated animals, sodium selenite pretreatment
often resulted in further elevation of BUN and creatinine
(Table 7).
WBC values were determined with a Brightline hemacytometer
and confirmed with a Coulter Cell Counter model B. A slight
protection of the white blood cells was seen on both days 3 and
5 (although this was not statistically significant on day 3) in
animals injected with 16.5 mg/kg tetraplatin followed 0.5 hr
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TABLE  6
Effect of DDTC and WR-2721 on Plasma Parameters in
Fischer 344 Rats Treated with Tetraplatin^
BUn'^ Creatinine^ WBc'^ ^Treatment N (mg/dl) (mg/dl) (cells/ml)  X 10"°
Vehicle 21       18.4 + 0.6 0.56 ± 0.05 4.9 ± 0.1
Day 3
16.5 mg/kg TP :    21      28.8 ± 2.5* 0.89 ±0.06* 1.9 ±0.1*
16.5 mg/kg TP + 5        17.7 ± 0.9***      0.55 ± 0.04*** 2.3 ± 0.1
750 mg/kg DDTC
16.5 mg/kg TP + 12      21.3 ±1.3***      0.64 ± 0.03*** 1.4 ±0.05**
200 mg/kg WR-2721
Day 5 ';    ;:
16.5 mg/kg TP 14      40.9 ±  7.1* 1.09 ± 0.10* 1.3 ± 0.05*
16.5 mg/kg TP +   5   16.3 ± 0.8**   0.42 ± 0.02**    1.8 ±0.7**
750 mg/kg DDTC
16.5 mg/kg TP +    12  18.5 ± 0.9**   0.52 ± 0.07**    1.4 ± 0.05
200 mg/kg WR-2721
^Animals were treated with DDTC 0.5 hr after tetraplatin or with WR-2721
0.5 hr before tetraplatin.    DDTC, diethyldithiocarbamate, WR-2721,
S-2(3-aminopropylamino)ethylphosphorothioic acid, and TP, tetraplatin.
Mean ± standard error.    BUN, creatinine and WBC measured as described
in Materials and Methods.
*Statistically different from controls  (p < 0.01).
**Statistically different from the TP group (p < 0.01).
***Statistically different from the TP group (p < 0.05).
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TABLE 7
Effect of Sodium Selenite on Plasma Parameters in
Fischer 344 Rats Treated with Tetraplatin
Treatment N
bun"^
(mg/dl)
Creatinine
(mg/dl)
WBC'^    A(cells/ml) X 10"^)
Vehicle 21 18.4 ± 0.6 0.56 ± 0.05 4.9 ± 0.1
Day 3
16.5 mg/kg TP 21 28.8 ± 2.5* 0.89 ± 0.06* 1.9 ± 0.1*
16.5 mg/kg
0.5 mg/kg
TP +
NaSe
5 42.1 ± 6.8 1.98 ± 0.31** 3.6 ± 0.6
16.5 mg/kg
1.0 mg/kg
TP +
NaSe
5 85.5 + 42.7 1.12 ± 0.18 2.5 ± 0.2
16.5 mg/kg
2.0 mg/kg
TP +
NaSe
5 100  ±42.3 2.40 ± 0.90 3.5 ± 0.9
Day 5
16.5 mg/kg TP + 14 40.9 + 7.1* 1 .09 ± 0.10* 1.3 ± 0.05*
16.5 mg/kg
0.5 mg/kg
TP +
NaSe
4 114.3 ± 39.0 2.80 ± 1.25 1.4 ± 0.05
16.5 mg/kg
1.0 mg/kg
TP +
NaSe
4 51.4 ± 9.2 1.31 ± 0.15 1.5 ± 0.1
16.5 mg/kg
2.0 mg/kg
TP +
NaSe
3 31.7 ± 9.4 1.04 ± 0.16 1.5 ± 0.07
^Animals treated with NaSe 4 hr before tetraplatin. NaSe, sodium selenite
and TP, tetraplatin.
Mean ± standard error. BUN, creatinine and WBC were measured as described
in Materials and Methods.
*Statistically different from controls (p < 0.01).
**Statistically different from the TP group (p < 0.05).       "
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later by 750 mg/kg DDTC (Table 6). WR-2721 (200 mg/kg)
pretreatment offered no protection of the circulating
leukocytes either on day 3 or day 5. With sodium selenite
pretreatment (0.5, 1.0 or 2.0 mg/kg), an apparent protection
was seen on day 3 (although this was not statistically
significant) but not on day 5 (Table 7). Since sodium selenite
afforded no significant protection based on any of the
parameters tested, studies with this agent were discontinued at
this point.
Platelets, lymphocytes, and neutrophils + monocytes were
measured in randomly selected animals on day 5 of the study
using a Technicon H*l Flow Cytometer as described in Materials
and Methods. The data showed that platelets in rats receiving
16.5 mg/kg tetraplatin decreased markedly when compared to
control animals and that DDTC treatment offered significant
protection (Table 8). DDTC-rescue also resulted in moderate
protection of the circulating lymphocytes (Table 8).
Neutrophils and monocytes were not affected by tetraplatin to
the same extent as lymphocytes and DDTC appeared to offer no
protection of those cells. WR-2721 did not appear to protect
any of the cells measured.
Histological examination was performed on day 5 on
representative animals receiving 16.5 mg/kg tetraplatin, 16.5
mg/kg tetraplatin followed by 750 mg/kg DDTC, or 16.5 mg/kg
tetraplatin preceded by 200 mg/kg WR-2721 (Table 9). The organs
were immediately removed, washed with normal saline and
TABLE  8
Platelet, Lymphocyte and Neutrophil  + Monocyte Cell Number
for Tetraplatin-Treated Rats with and without Protective Agent^
Platelets      ^ Lymphocytes Neutrophils + MonocytesTreatment N (cells/ml) x 10"° (cells/ml) x 10-6 (cells/ml) x IQ-o)
1.61 ± 0.18*
0.66 ± 0.19
0.65 ± 0.07
0.60 ± 0.07
^The parameters were measured on day 5 only.
Mean ± standard error. Platelets, lymphocytes and neutrophils + monocytes were measured as
described in Methods.
*
Vehicle 4 704 ±  30* 3.10 ± 0.16*
16.5 mg/kg TP 3 194 ± 38 0.61  ± 0.06
16.5 nig/kg TP +
750 mg/kg DDTC
3 324 ±  10* 1.23 + 0.08*
16.5 mg/kg TP +
200 mg/kg WR-2721
3 185 ± 25 0.70 ± 0.01
Significantly different from TP-treated group (p < 0.05).
TABLE 9
The Effect of DDTC and WR-2721  on Histology in
Fischer 344 Rats Treated with Tetraplatin
Experimental  Groups
Organ Histologic Changes Control TP
TP+
DDTC
TP+
WR-2721
Stomach Mucosal  ulceration and atrophy
Small
Intestine   Villous atrophy and attenuation
Large     Villous atrophy and attenuation
Intestine   Reduction of goblet cells
Kidney     Coagulative necrosis in tubules
Protein fluids and distention of tubules
Thymus     Atrophy and reduction of lymphocytes
number
Spleen Atrophy and reduction in size of
lymphoid follicles
Reduction of T-cell  collars
Reduction of hematopoietic cells
+++
0 +++ 0 0
0 ++ 0 0
0 ++ 0 0
0 ++ 0 0
+++ +++
0 ++ 0 ++
0 +++ 0 ++
0 +++ 0 ++
0 = normal; + = mild changes; ++ = moderate changes; +++ = severe changes
All tissues were taken on day 5 after injection.
The doses used were: tetraplatin, 16.5 mg/kg; DDTC, 750 mg/kg; WR-2721, 200 mg/kg,
K5
00
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processed for histological examination as described in
Materials and Methods.
The thymus and spleen appeared to be the major target
organs for tetraplatin-induced damage. Tetraplatin exposure
resulted in marked atrophy and depletion of lymphocytes in the
thymus and obliteration of the normal architecture. Similar
damage was seen in rats pretreated with WR-2721. Treatment with
DDTC resulted in only slight thymic atrophy and a much less
severe reduction of lymphocyte cellularity in the cortex and
medulla (Table 9). Splenic alterations in animals receiving
tetraplatin included atrophy of lymphoid follicles, congestion
and loss of hematopoietic cells. The spleens of rats receiving
WR-2721 before tetraplatin incurred similar types of lesions,
but DDTC-protected rats had spleens similar to those of control
animals.
Pathological changes in the small and large intestine
associated with tetraplatin treatment included shortened villi
which were fused and attenuated and a reduction in the number
of goblet cells. The small and large intestine in DDTC- and WR-
2721-protected rats were normal (Table 9). In the stomach,
tetraplatin caused segmental mucosal alterations, which were
accompanied by massive submucosal hemorrhage, edema and
inflammation. Only slight pathological changes were observed in
the stomach of animals protected with WR-2721 or DDTC.
Renal damage in those tetraplatin-treated rats which
showed elevated BUN and creatinine was characterized by
dilation and distention of renal tubules with proteinous
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fluids. There were scattered foci of regenerated renal tubular
epithelial cells. Rats which did not show elevated BUN and
creatinine in response to tetraplatin treatment had essentially
normal renal histology but suffered from damage comparable to
that of responders in other organ systems (i.e., spleen,
thymus, stomach, large and small intestine). Those rats
receiving DDTC- or WR-2721-protection did not exhibit any
pathological changes in the kidney (Table 9).
Discussion
From the data presented here and that reported by others
(Smith et al., 1988a), it is apparent that tetraplatin is
significantly less nephrotoxic than cisplatin. This
investigation confirms previous reports that myelosuppression
and gastrointestinal toxicity are more severe than
nephrotoxicity and may be dose-limiting in tetraplatin
treatment (Smith et al., 1988b).
It is interesting to note that tetraplatin nephrotoxicity
did not appear consistently in all treated animals. About 25%
of the animals receiving 16.5 mg/kg tetraplatin showed no
indication of nephrotoxicity either in plasma assays or in
pathological examination. In those animals receiving 12 mg/kg
tetraplatin, approximately half of the animals showed no
indication of nephrotoxicity. However, all rats receiving 12 or
16.5 mg/kg tetraplatin showed similar myelosuppressive effects
as indicated by reduced WBC. Additionally, the animals
receiving 16.5 mg/kg showed decreases in platelet levels and
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histological evidence of thymus and spleen damage. Therefore,
the hematological and histological evidence in tetraplatin-
treated rats confirmed that all iv injections were successful.
Smith et al. (1988a) also found this phenomenon to occur in
rats treated with tetraplatin. They reported that all rats
treated with 2 6.7 umole/kg tetraplatin had similar renal
platinum concentrations, but upon histological examination not
all contained necrotic lesions in the kidney. As a result, a
number of their animals did not develop any symptoms of
nephrotoxicity during a 15-day experiment (Smith et al.,
1988a).
There appeared to be no dose-response relationship between
the 12 and 16.5 mg/kg tetraplatin doses (Table 2 and 6) when
response was measured by BUN and creatinine levels. However, on
both days 3 and 5, the 12 mg/kg data was extremely variable
making direct comparison with the 16.5 mg/kg data difficult. On
day 5 of the study, the higher BUN and creatinine values for
the 12 mg/kg dose could be explained by the large number of
deaths in the 16.5 mg/kg group (Table 6). Since these deaths
occurred for the most part in animals with the highest BUN and
creatinine values on day 3, it would be assumed that their
values would be the highest on day 5. Additionally, a large
number of the animals surviving to day 5 of the study would be
non-responders. But for the day 3 data, the same argument could
not be substantiated since all of the animals in the 12 and
16.5 mg/kg tetraplatin groups were still alive.
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These studies indicate that both DDTC (750 mg/kg at 0.5 hr
after a 12 or 16.5 mg/kg tetraplatin injection) and WR-2721
(200 mg/kg at 0.5 hr before a 16.5 mg/kg tetraplatin injection)
were effective in ameliorating tetraplatin-induced
nephrotoxicity in the Fischer 344 male rat (Tables 2,6,7 and
9). Results similar to these have been reported with cisplatin
followed by DDTC (Borch and Pleasants, 1979; Borch et al.,
1980) or preceded by WR-2721 (Yuhas and Culo, 1980).
Gastrointestinal toxicity was also reduced significantly by the
use of DDTC and WR-2721 (Table 9). However, only DDTC was able
to reduce the myelosuppressive effects of tetraplatin (Tables 8
and 9). Twentyman (1983) has also reported that white blood
cells are not protected by WR-2721 pretreatment in cisplatin-
treated rats.
In this investigation, sodium selenite was ineffective in
protecting against tetraplatin-induced damage (Table 7).
However, recent studies suggest sodium selenite can be
effective when administered concomitantly (Ohkawa, 1988) or at
1 hr before cisplatin (Baldew et al., 1989). These particular
protocols were not examined in the current studies.
This study indicates that DDTC may be the most efficacious
compound for reducing tetraplatin toxicity. DDTC not only
reduced nephrotoxicity and gastrointestinal toxicity, but it
also provided partial protection of the hematopoeitic system.
WR-2721 was effective in protecting against renal and
gastrointestinal toxicity, while sodium selenite afforded
little or no protection with the protocols utilized.
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Three mechanisms have been proposed for the selective
protection of normal tissues by WR-2721. Yuhas and coworkers
(Yuhas 1980; Yuhas et al., 1982) have proposed that WR-2721 is
actively transported into normal tissues but is slowly absorbed
by solid tumors via facilitated diffusion. Calabero-Jones et
al. (1988) have proposed that WR-2721 is selectively activated
by dephosphorylation to WR-1065, the corresponding aminothiol,
at or near the membrane surface of normal tissues; and that WR-
1065 enters the cell by passive diffusion. Finally, Issels and
Nagele (1989) have shown that WR-2721 can either increase or
decrease intracellular glutathione levels depending on cell
type. Therefore, the organ specific protection seen with WR-
2721 could result in differential dephosphorylation or
differential effects on glutathione levels in the kidney and
gastrointestinal system compared to the thymus, spleen, and
bone marrow.
To date, there are no data indicating that DDTC is
selectively absorbed by normal tissue as is the case with WR-
2721 and the mechanism of protection is unknown. Theories of
the mechanism of DDTC protection include reversal of platinum
monoadducts (Bodenner et al., 1986), reversal of platinum
inactivated renal enzymes (Dedon and Borch, 1987), and possible
stimulatory effects on the bone marrow (Gringeri et al., 1988).
Because selective uptake of DDTC is not required and it appears
that DDTC exerts its effect via multiple pathways, DDTC appears
to have a broader range of protective activities when compared
to WR-2721.
34
References
Baldew, G.S., van den Hamer, C.J.A., Los, G., Vermeulen, N.P.E.,
de Goeij, J.J.M., and McVie, J.G.   (1989).    Selenium-induced
protection against cis-diarTiniinedichloroplatinum(II)    nephrotoxicity
in mice and rats.    Cancer Res.  49, 3020-3023.
Berry, J-P., Pauwells, C, Tlouzeau, S., and Lespinats, G.   (1984).    Effect
of selenium in combination with cis-diamminedichloroplatinum(II)
in the treatment of murine fibrosarcoma.    Cancer Res.  44, 2864-2868.
Bodenner, D.L., Dedon, P.C, Keng, P.C, and Borch, R.F.   (1986).    Effect
of diethyldithiocarbamate on cis-diamminedichloroplatinum(II)-
induced cytotoxicity, DNA cross-linking,  and y-glutamyl   transpeptidase
inhibition.    Cancer Res.  46, 2745-2750.
Borch,  R.F.,  Katz, J.C, Lieder,  P.H.  and Pleasants, M.E.   (1980).
Effect of diethyldithiocarbamate rescue on tumor response to cis-
platinum in a rat model.    Proc. Natl. Acad. Sci.  77, 5441-5444.
Borch, R.F., and Pleasants, M.E. (1979). Inhibition of cis-platinum
nephrotoxicity by diethyldithiocarbamate rescue in a rat model.
Proc.  Natl.  Acad.  Sci.   76, 6611-6614.
Calabro-Jones,  P.M., Aguilera, J.A., Ward, J.F., Smoluk,  G.D., and
Fahey,  R.C.   (1988).    Uptake of WR-2721  derivatives by cells  in
culture:    identification of the transported form of the drug.
Cancer Res.  48, 3634-3640.
Dedon, P.C, and Borch, R.F. (1987). Characterization of the reactions
of platinum antitumor agents with biologic and nonbiologic sulfur-
containing nucleophiles.    Biochem. Pharmacol.  36, 1955-1964.
Gringeri, A., Keng, P.C, and Borch, R.F.   (1988).    Diethyldithiocarbamate
inhibition of murine bone marrow toxicity caused by cis-diamminedi-
chloroplatinum(II)  or diammine  (1,1-cyclobutanedicarboxylato)platinum
(II).    Cancer Res.    48,  5708-5712.
Issels, R.D., and Nagele, A.   (1989).    Promotion of cystine uptake,
increase of glutathione biosynthesis, and modulation of glutathione
status by S-2(3-aminopropylamino)ethylphosphorothioic acid (WR-2721)
in Chinese hamster cells.    Cancer Res. 49, 2082-2086.
Ohkawa,  K., Tsukada, Y., Dohzono, H., Koike, K., and Terashima, Y.  (1988).
The effects of co-administration of selenium and    cisplatin  (CDDP)
on CDDP-induced toxicity and anticancer activity.    Br. J.  Cancer 58,
38-41.
35
Saunders, A.M., Groner, W., and Kusnetz, J.   (1971).    A rapid automatic
system for differentiating and counting white blood cells.     In
Advances in Automated Analysis, Teknicon International  Congress,
p.  437.    Thurman Associates, Miami, Florida.
Smith, J.H.,  Smith, M.A., Litterst, C, Copley, M., Uozumi, J., and
Boyd, M.R.   (1988a).    Comparative toxicity and renal  distribution
of the platinum analogs tetraplatin, CHIP, and cisplatin at
equimolar doses in the Fischer 344 rat.    Fundam. Appl. Toxicol.
10,  45-61.
Smith, M.A. ,  Smith, J.H.,  Litterst, C, Copley, M., Uozumi, J.,  and
Boyd, M.R.   (1988b).    In vivo biochemical  indices of nephrotoxicity
of the platinum analogs tetraplatin, CHIP, and cisplatin in the
Fischer 344 rat.    Fundam. Appl. Toxicol.  10, 62-72.
Twentyman,  P.R.   (1983).    Modification by WR-2721  of the response to
chemotherapy of tumors and normal  tissues in the mouse.    Br. J.
Cancer.  47, 57-63.
Wyrick,  S.D.  and Chaney, S.G.   (1988).    Tritiated platinum anticancer
agents containing the trans-(d,l)-l,2-diaminocyclohexane carrier
ligand.    J.  Labeled Cmpds.  Radiopharmaceut. 25, 349-357.
Yuhas, J.M.   (1980).    Active versus passive absorption kinetics as the
basis for selective protection of normal  tissues by S-2(3-
aminopropylamino)ethylphosphorothioic acid.    Cancer Res. 40,
1519-1524
Yuhas, J.M., and Culo,  F.     (1980).    Selective inhibition of the
nephrotoxicity of cis-diamminedichloroplatinum(II)  by WR-2721 without
altering its antitumor properties.    Cancer Treat.  Rep. 64, 57-64.
Yuhas, J.M., Davis, M.E., Glover, D., Brown, D.Q., and Ritter, M.   (1982).
Circumvention of the tumor membrane barrier to WR-2721  absorption by
reduction of drug hydrophilicity.    Int. J.  Radiat. Oncol.  Biol.
Phys.   8, 519-522.
CHAPTER III
PHARMACOKINETICS AND BIOTRANSFORMATION STUDIES OF
TETRACHLORO(d,l-trans)1,2-DIAMIN0CYCL0HEXANEPLATINUM(IV) WITH
AND WITHOUT DIETHYLDITHIOCARBAMATE ADMINISTRATION
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Introduction
Based on the efficacy of DDTC in the toxicity studies
(Chapter 2), tetraplatin pharmacokinetic and biotransformation
experiments were carried out with DDTC. To date, all
experiments involving tetraplatin biotransformation products
have been performed in vitro. Mauldin et al. (1988) have shown
that a number of different platinum biotransformation products
(including methionine-platinum complexes and a
monoaquamonochloro species) result from incubation of the L1210
cell line with PtCl2(trans-dach). There has been no in vivo
experimentation with tetraplatin and DDTC. Therefore, the goal
of these studies was to compare the total platinum
pharmacokinetics and the tetraplatin biotransformation products
that result with and without DDTC administration.
Materials and Methods
A. Reagents
[4 , 5- H2 (n) ] -Trans- (d, 1) -1, 2-diaminocyclohexane (["^H] -
trans-dach, S.A. = 402 mCi/mmole) , [4,5--^H2 (n) ]-trans-l,2-
diaminocyclohexanetetrachloroplatinum(IV) ([ H] tetraplatin,
S.A. = 419 mCi/mmole) , and [4 , 5--^H2 (n) ]-trans-1, 2-
diaminocyclohexanedichloroplatinum(II) (["^H] PtCl2 (trans-dach) ,
S.A. = 402 mCi/mmole) were kindly provided by Dr. Steven Wyrick
(Department of Medicinal Chemistry, University of North
Carolina, Chapel Hill, NC). The synthesis of these compounds
has been previously described (Wyrick and Chaney, 1988).
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^195ltlp^-| Potassium hexachloroplatinate (initial S.A. of 27.1
mCi/mmole) was obtained from the Oak Ridge National Laboratory,
Oak Ridge, TN. ["' ͣ^^^Pt] Tetraplatin was synthesized by a one
step synthesis previously described by Correa and Kepler
(1986). Both the [^H] and [^^^™Pt] tetraplatin were dissolved
by sonication in 0.15 M NaCl for 1-2 hr followed by filtration
with 0.2 urn Acrodisc filter from Gelman Sciences (Ann Arbor,
MI). Purity of the [ H] tetraplatin was assessed by HPLC and
found to be 95% pure. Sodium diethyldithiocarbamate (DDTC) was
obtained from the Sigma Chemical Co. (St. Louis, MO). HPLC
grade methanol and acetonitrile were purchased from Fisher
Scientific (Fair Lawn, NJ). Water used with solvents and for
dissolving of compounds was purified by a Barnstead Nanopure
water purification system with an organics filter. All eluents
used in HPLC analysis were degassed and filtered through a 0.22
urn Duropore filter (GVWP, Millipore Corp., Bedford, MA) for
non-aqueous solutions or a MF-Millipore filter (GSWP, Millipore
Corp.) for aqueous solutions prior to use. YMT ultrafiltration
membranes with a molecular weight cut-off of 30,000 were
obtained from Amicon (Danvers, MA). Salmon testes DNA was
purchased from the Sigma Chemical Co. All other chemicals were
reagent grade or better.
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B. In Vivo Biotransformation Assays
Adult male Fischer 344 rats were obtained from Charles
River Breeding Laboratories (Raleigh, NC). They weighed 3 00-4 00
g and were housed on a 12-hr light/dark cycle in stainless
steel cages with room temperature maintained at 22°C. The
animals were allowed Purina rodent chow and water ad libitum.
At least a one-week acclimation period was allowed prior to
cannulation. All rats were anesthetized with Ketamine/Rompun
(25 and 5 mg/kg, respectively) and cannulated via the right
jugular vein by insertion of a polyurethane tube. To prevent
clotting, 0.1 ml of 3.3 USP units/ml of heparin was injected
into the cannula to remove any residual blood. A 1-day recovery
period was allowed before injection of the platinum drug. Six
rats were injected with 12 mg/kg [-^H] tetraplatin and one with
10 mg/kg [ ͣ' ͣ^^^Pt] tetraplatin via the jugular vein catheter. Of
the six rats receiving [ H] tetraplatin, three rats also
received 750 mg/kg DDTC ip 0.5 hr after the [-^H] tetraplatin.
All tetraplatin solutions were filtered with an Acrodisc filter
prior to injection. Both radioactive drugs were injected into
the rats over one a minute time period. Blood samples were
taken at seven different time points following tetraplatin
administration: 3.5 min, 7.5 min, 15 min, 30 min, 1 hr, 2 hr,
and 3 hr. The blood was immediately centrifuged at 3500 g for
3-5 min at 4°C. A plasma sample was obtained for each time
point, diluted 1:5 into cold 0.15 M NaCl and counted on either
a LKB model 1215 liquid scintillation counter or a Nuclear-
Chicago model 1185 gamma counter for [-^H] and [^^^"'Pt]
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tetraplatin, respectively. The remaining sample was filtered
through an Amicon YMT membrane by centrifugation at 2000 g for
20 min at 4°C. Filtered samples were counted as previously
described and then frozen at -80°C overnight. Frozen samples
were thawed and 100,000 to 200,000 CPM were injected onto a
reverse phase HPLC column. Individual reverse phase HPLC
fractions were further characterized by cation exchange HPLC.
C. HPLC Separation
HPLC separations were performed with a LKB system equipped
with two model 2150 HPLC pumps, a model 2152 LC controller, and
a Rheodyne model 7125 sample port fitted with either a 200 ul,
500 ul, 1 ml, or 5 ml loop. Reverse phase HPLC was performed on
two columns, a 4.6 X 250 mm Whatman Partisil 5 ODS-3 column
with a 5.6 X 50 mm guard column packed with pellicular ODS, and
a 4.6 X 250 mm Phenomenex Zorbax ODS column. The guard column
was repacked after the completion of each experiment. The
reverse phase eluent for the Partisil 5 ODS-3 column consisted
of two buffers: buffer A, 5 mM 1-heptanesulfonate at pH 3.4 (pH
was adjusted downward with glacial acetic acid), and buffer B,
90% (v/v) methanol in water. The elution profile was 10 min of
buffer A, a 30 min linear gradient from A to B, followed by 20
min at B. The flow rate was held constant at 1 ml/rain. The
column was allowed to reequilibrate on buffer A for 30 min
after the gradient had finished. The reverse phase eluent for
the Zorbax ODS column consisted of isocratic water with a flow
rate of 0.5 ml/min. Cation exchange HPLC was carried out on a
4.6 X 250 mm Phenomenex 10 SCX column with a 4.6 X 50 mm guard
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column packed with pellicular SCX. The guard column was
repacked following each experiment. The cation exchange eluent
consisted of two buffers: buffer A, 50 mM KH2PO4, 15%
acetonitrile, and buffer B, 50 mM KH2PO4, 15% acetonitrile, and
1 M KNO3. These buffers were used at two pHs, pH 2.3 and pH
4.0. The pH was adjusted downward with phosphoric acid. The
elution profile for cation exchange was the same as that for
the reverse phase gradient except the initial buffer A eluted
for 20 min instead of 10 min. With both the reverse phase and
cation exchange HPLC, 1 ml fractions were collected. For the
[ ͣ^H] tetraplatin, aliquots were counted directly in ScintiVerse
BD (Fisher Scientific) . For the [ ͣ' ͣ^^mPt] tetraplatin, the 1 ml
fractions were counted directly on a gamma counter.
Chromatographic data were collected with the Ultraterm software
package (LKB), quantitated with the Chromatochart software
package (Interactive Microware, Inc., State College, PA) and
graphed with the Sigma-Plot software package (Jandel
Scientific, Sausalito, CA) on an IBM compatible personal
computer.
D. DNA Binding Assay and Standards
Measurement of DNA binding activity has been described
previously (Mauldin et al., 1988). All solutions for the DNA
binding assay were prepared on the day of the experiment. For
the platinum(II)-(DDTC) complex, 50 uM DDTC was allowed to
react with 10 uM [^H] or [^^^"'Pt] tetraplatin for 30 min at
37°C. The platinum(II)(methionine)(trans-dach) complex was
either prepared from Pt(mal)(trans-dach) as described
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previously (Mauldin et al., 1986) or by incubating 110 uM
j-195mp^-] tetraplatin with 120 uM sodium ascorbate and either
0.1 or 10 mM methionine for 24 hr at 37°C. These standards were
stored at 4°C for up to two weeks with no change in
composition.
Results
For the biotransformation studies, a 12 mg/kg dose was
selected.  The 16.5 mg/kg dose was not practical since [^H]
tetraplatin could not be dissolved at concentrations greater
than 2 mg/ml. As a result, an unacceptably large volume would
have had to been injected to achieve the 16.5 mg/kg dose. The
initial part of the biotransformation experiment was intended
to measure the amount of total, free and protein-bound platinum
in rat plasma over a 3 hr time course. A comparison of these
values for rats treated with 12 mg/kg tetraplatin alone or 12
mg/kg tetraplatin followed by 750 mg/kg DDTC 0.5 hr later is
shown in Figure 1. DDTC treatment resulted in a significant
decrease in the amount of total platinum , protein-bound
platinum and percent platinum protein-bound. Consequently, the
amount of free platinum in the plasma increased after the DDTC
injection. It should be noted that the term "platinum" could
include the [-^H] trans-dach ligand since the tritium label is
placed on this group and not on the platinum itself.
After determination of the platinum concentrations, the
filtered plasma samples were injected onto a reverse phase HPLC
column to determine the elution profiles of the tetraplatin
biotransformation products. The gradient and eluents used for
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Figure 1.    [3h] Tetraplatin Pharmacokinetics in Fischer 344 Male Rats.
[3h] Tetraplatin (12 mg/kg) was injected iv into 6 rats at
time 0.    Three of the rats were treated with 750 mg/kg
DDTC ip at 0.5 hr.    Plasma samples were obtained at 3.5 min,
7.5 min,  15 min, 30 min.  1  hr, 2 hr, and 3 hr and analyzed
as described in Materials and Methods.    Platinum concentra¬
tions were determined based on the specific activity of the
[3h] tetraplatin (419 mCi/mnole) and plotted on a semilog
scale.    Figure lA, total [^Hj-labeled biotransformation
products; Figure IB, free [3H]-labeled biotransformation
products; Figure IC, protein bound [^Hl-labeled biotrans¬
formation products; Figure ID, percentage of the [3h]-
labeled biotransformation products which were protein bound.
Key:    0 ------- 0, 12 mg/kg [^H] tetraplatin alone.
A ------ i, 12 mg/kg [^H] tetraplatin followed by
750 mg/kg DDTC at 0.5 hr.
44
reverse phase HPLC (Partisil 5 ODS-3 column) are described in
Materials and Methods. The reverse phase profiles for plasma
samples from animals treated with tetraplatin and tetraplatin-
DDTC are shown in Figures 2 and 3, respectively. The labeling
of peak fractions was based on nomenclature described
previously (Mauldin et al., 1986). When tetraplatin was
administered alone, the reverse phase HPLC profiles consisted
of 4 to 7 distinct peaks. At earlier times (7.5 to 30 min), the
predominant peak was b, while as the experiment progressed,
peaks a, e, f and g become predominant (Figure 2). Peaks e and
f were not sufficiently resolved at all time points to be
quantitated separately. Thus, in all subsequent calculations,
they are added together and referred to as the e+f peak.
It can be seen from Figure 3 that after DDTC injection
most of the [3H] labeled biotransformation products eluted as a
single peak, the 35 min fraction (peak g). This conversion was
quite rapid, occurring within the first 30 min following the
DDTC injection (Figure 3A). Since free trans-dach also eluted
at 35 min under these conditions (see position of the arrow.
Figures 2 and 3), the peak at 35 min could represent either a
mono-DDTC bidentate platinum(II) complex containing the [^H]
trans-dach carrier ligand similar to the ones described by Jain
et al. (1988) or free [-^H] trans-dach displaced from the bis,
bidentate DDTC-platinum(II) complex described by Dedon and
Borch (1987). Therefore, as a control, DDTC was incubated with
either [^H-dach] or [^^^"'pt] tetraplatin (Figure 3D). Two
distinct reverse phase profiles were observed. Aliquots from
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Figure 2. Reverse Phase Profiles of [^H] Tetraplatin Biotransformation
Products. L^H] Tetraplatin (12 mg/kg) was injected iv into
a Fischer 344 rat. At various times after injection,
filtered plasma samples were analyzed by reverse phase
HPLC as described in Materials and Methods. 2A, 7.5 min;
2B, 15 min; 2C, 30 min; 2D, 1 hr; 2E, 2 hr; 2F, 3 hr.
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Figure 3.    Reverse Phase Profiles of [^H] Tetraplatin Biotransformation
Products in the Presence of DDTC.    [3h] Tetraplatin
(12 mg/kg) was Injected iv into 3 Fischer 344 rats and
followed 0.5 hr later by 750 mg/kg DDTC ip.    Filtered
plasma samples were analyzed by reverse phase HPLC as
described in Materials and Methods.    3A, 1 hr after tetra¬
platin (0.5 hr after DDTC); 3B, 2 hr after tetraplatin
(1.5 hr after DDTC); 30. 3 hr after tetraplatin (2.5 hr after
DDTC); 3D, 50 yM DDTC + 10   yM tetraplatin Incubated 30 min
at 37"'C (0--------0. [3h] tetraplatin; i----------i. [^^Ht)
tetraplatin).
Key:    (t) represents the position where free [^H] trans-dach
eluted for each run.
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the [-^H] tetraplatin plus DDTC incubation eluted at 3 5 min
while aliquots from the [^^^"'Pt] tetraplatin plus DDTC
incubation eluted at 50 min. Similar incubations of [-^H]
PtCl2(trans-dach) with DDTC also gave a single peak eluting at
35 min (data not shown). These data  suggest that the DDTC is
both reducing the tetraplatin to PtCl2(trans-dach) and
displacing the ["^H] trans-dach ligand to form a bis, bidentate
platinum(II)-DDTC complex.
To further characterize the biotransformation products
observed on reverse phase HPLC, selected reverse phase
fractions were fractionated on cation exchange HPLC as
described in Materials and Methods. Figure 4 shows the
characterization of peak g on cation exchange HPLC. The g peak
from animals treated with tetraplatin only gave two peaks on
cation exchange. TJie first peak eluted from 3 0-32 min on cation
exchange at pH 4.0 (Figure 4A) and from 33-35 min at pH 2.3
(Figure 4B) . This peak coeluted with the ["^H] trans-dach used
to standardize the column (see arrows) and was the only peak
observed when peak g from tetraplatin-DDTC-treated animals was
analyzed on cation exchange HPLC. The second peak eluted at 35-
37 and 42-44 min for pH 4.0 and 2.3, respectively (Figures 4A
and 4B). The later eluting peak has been previously identified
(Mauldin et al., 1986) as a mixture of the mono-methionine,
bidentate and bis-methionine, monodentate platinum(II)
complexes. This peak was not present in the animals treated
with DDTC (Figures 4C and 4D). Additionally, peak g from a [^H]
tetraplatin plus DDTC incubation was run at both pH 4.0 and 2.3
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Figure 4. Cation Exchange Profiles of Reverse Phase Peak g. Cation
exchange HPLC was used to characterize the g peaks (35 min
fraction) from Figs. Z and 3. Cation exchange HPLC was
performed at pH 4.0 and 2.3 as described in Materials and
Methods. 4A, tetraplatin alone, 2 hr, peak'g from Fig. 2E,
pH 4.0; 4B, same as Fig. 4A except at pH 2.3; 4C, tetraplatin
+ DDTC, 3 hr, peak g from Fig. 3C, pH 4.0; 40, same as
Fig. 4C except at pH 2.3; 4E, 50 yM DDTC + 10 uM tetraplatin
incubated 30 min at S^C (0 ----0, [^H] tetraplatin, 35 min
fraction; k — • —A,[195mpt] tetraplatin, 50 min fraction),
pH 4.0; 4F, same as Fig. 4E except at pH 2.3.
Key: (v) represents the position where free [^H] trans-dach
eluted for each run.
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(Figures 4E and 4F, respectively) and the 50 min fraction from
a [ ͣ' ͣ^^"'Pt] tetraplatin plus DDTC incubation was run at pH 2.3
(Figure 4E). These standards again confirm that the early-
eluting portion of peak g on cation exchange was most likely
free [^H] trans-dach.
Gibbons et al. (1989) have determined in their studies
that tetraplatin and its reduced form, PtCl2(trans-dach), elute
at 9 and 11 min, respectively, on a Partisil 5 ODS-3 reverse
phase column. On this basis, it would appear that most of the
tetraplatin had been converted to PtCl2(trans-dach) at all the
times tested (Figure 2). However, the Partisil 5 ODS-3 column
did not offer sufficient resolution to quantitate the
compounds. To achieve a better resolution of the two compounds,
a Zorbax ODS column was used (Materials and Methods). Zorbax
separations on 7.5 and 15 min samples (Figure 5) were performed
to quantitate the tetraplatin (24 min) and the PtCl2(trans-
dach) (35 min). At times later than 15 min, the PtCl2(trans-
dach) peak was small enough to allow the quantitation of the
two peaks from the Partisil 5 ODS-3 column.
The monoaquamonochloro platinum(II) compound has been
previously located in the e+f peak (Mauldin et al., 1986). The
amount of monoaquamonochloro species in peaks e+f was
quantitated by the DNA binding assay described in Materials and
Methods. As is seen in the Table 1, at early times the e+f peak
was entirely the monoaquamonochloro species. But as time
progressed, that compound was slowly replaced by other
biotransformation products which were not reactive towards DNA.
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Figure 5. Reverse Phase Profiles of ['^H] Tetraplatin Biotransformation
Products with the Zorbax Column. The 7.5 min and 15 min
samples described in Fig. 2 were analyzed by reverse phase
HPLC to determine the percentage of tetraplatin and PtCl„-
(trans-dach) in peak b. The conditions for the Zorbax
separation are described in the Materials and Methods. 5A,
7.5 min, tetraplatin only; 5B, 15 min, tetraplatin only.
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TABLE 1
Reactivity Towards DNA of Selected Tetraplatin
Biotransformation Products
Time
Point ^1 e+f 9
7.5 min — 49.1 —
15 min — 51.6 —
30 min 10.5 33.2 23.7
1 hr 2.7 11.2 13.0
3 hr 0.0 5.6 6.3
1 hr* >- 8.02 2.27
2 hr* -- 6.27, 7. 10 3.0, 3.7
^Values are percentage of input counts bound to DNA in 30 min
at 37°C. Where there are two values, each was derived from
separate experiments. DNA binding was determined as
described in Materials and Methods.
*Percentages for 16.5 mg/kg tetraplatin followed by 750 mg/kg
DDTC at 0.5 hr.
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The reactivity of the g peak towards DNA was minimal, as has
been reported previously (Mauldin et al., 1988).
By using the specific activity of the [ H] tetraplatin and
the area under each peak from reverse phase HPLC, the amounts
T . . .of [ H] labeled biotransformation products in each peak
fraction were calculated (Table 2) . Peaks a, d-j^, 6.2  and h have
not been further identified. The platinum compounds represented
by b, e+f and g were further characterized by reverse phase
HPLC and cation exchange HPLC and DNA binding assays as
described above. Tetraplatin (b-|^) and PtCl2 (trans-dach) (b2)
were resolved by Zorbax reverse phase HPLC (Figure 5). The
monoaquamonochloro species in the e+f peak was quantitated by
the DNA binding assay (Table 1). Free trans-dach and the
platinum-methionine complexes were resolved from peak g by
cation exchange HPLC (Figure 4). A graphic summary of the
concentrations for selected peaks (tetraplatin-treated animals
only) over a 3-hr time course is shown in Figure 6. When
comparing concentrations of tetraplatin biotransformation
products for the tetraplatin alone and tetraplatin-DDTC-treated
animals, it was apparent that peaks g and h increased and peaks
b2 and d^^ decreased significantly after DDTC administration
(Table 2). The concentration of the monoaquamonochloro complex
also decreased after DDTC administration (Figure 6). The
concentrations of peaks a; dj and e+f were virtually unaffected
by DDTC administration.
An experiment with [-^^^"^Pt] tetraplatin was performed to
determine if the tetraplatin pharmacokinetics remained constant
TABLE  2
Concentration of Tetraplatin Biotransformation Products
Time a h ^^2 "i ^2 e+f g h
7.5 min 0.84(5)
±0.26
0.84(5)
±0.08
18.2(5)
±1.84
0.75(5)
± 0.20
1.10(5)
±0.32
5.81(5)
±0.78
2.48(5)
±0.36
.      ND
15 min 0.42(5)
±0.05
0.46(5)
± 0.05
7.85(5)
± 0.82
0.46(5)
± 0.12
0.55(5)
± 0.06
3.76(5)
± 0.41
1.92(5)
± 0.13
0.09(5)
± 0.05
30 min 0.36(5)
± 0.03
0.25(5)
± 0.06
2.58(5)
± 0.35
0.37(5)
± 0.09
0.40(5)
± 0.07
2.50(5)
±0.52
1.50(5)
± 0.23
ND
1  hr 0.51(3)
± 0.14
0.08(3)
±0.02
0.79(3)
± 0.17
0.38(3)
± 0.12
0.19(3)
± 0.07
1.96(3)
±0.35
1.28(3)
±0.32
0.01(3)
± 0.01
2 hr 0.45(2)
± 0.04
ND 0.38(2)
± 0.23
0.62(2)
± 0.44
0.15(2)
± 0.04
2.58(2)
± 0.49
1.78(2)
± 0.07
ND
3 hr 0.46(2)
±0.09
ND 0.40(2)
± 0.14
0.85(2)
± 0.65
0.07(2)
± 0.07
2.30(2)
± 0.15
1.92(2)
± 0.32
ND
1 hr* 0.22(2)
± 0.18
ND 0.37(2)
± 0.02
ND 0.18(2)
± 0.18
1.76(2)
± 0.24
13.0(2)
± 1.55
0.86(2)
± 0.24
2 hr* 0.49(3)
± 0.31
ND 0.27(3)
± 0.13
ND 0.24(3)
± 0.12
2.09(3)
± 0.30
8.05(3)
± 0.99
0.69(3)
± 0.06
3 hr* 0.78(2)
± 0.27
ND ND ND 0.16(2)
± 0.16
1.92(2)
± 0.14
8.69(2)
± 2.31
0.76(2)
± 0.09
yM concentration ± standard error. N is in parentheses. pM concentrations of individual components
were determined using the specific activity of [H^] tetraplatin. The distribution of peak a, b, d, d2,
e+f, g, and h was determined from data such as that shown in Figure 2. Peak b was further defined into
peaks b, and b2 from the data shown in Figure 6. j2
*Concentrations for 16.5 mg/kg tetraplatin followed by 750 mg/kg DDTC at 0.5 hr.
ND = not detectable at less than 0.01 uM.
Q_
10.00
t2\
I   ,
\ ͣͣ
1.00   h    '^\
\ A-
0.10
\
A
-A...
:o-
.....A
-A
-O
0.02   ' ͣͣ'' ͣ' ͣͣͣͣͣ' ͣ' ͣͣ''
n""
D
B
____-A
A--
«.—O"
' ' ' ' ͣ ͣ ' I ͣ ͣ ' ͣ ͣ I ͣ ͣ ͣ ͣ ' I I ͣ
0        60      120    180 0        60      120    180
TIME (MIN)-
54
Figure 6.    yiM'Concentrations of Platinum Biotransformation Products
following an Injection of 12 mg/kg [ H] Tetraplatin over a
3 hr Time Course.    Tetraplatin and PtCl2(trans-dach) were
quantitated by reverse phase HPLC on a Zorbax column (Fig. 5).
The other biotransformation products were quantitated by
reverse phase on a Partisil 5 ODS-3 column (Fig. 2).    Peaks e+f
were combined for quantitation because they were not adequately
resolved at all time points.    The contribution of the
monoaquamonochloro complex to peak e+f was determined by a DNA
binding assay (Table 2).    The contributions of free trans-dach
and the methionine complex to peak g (Fig. 2) were resolved by
cation exchange HPLC at pH 4.0 and 2.3 (Fig. 4).    A:    0 •   •   •   -0,
PtCl2(trans-dach); I --------I, tetraplatin; A — ͣ —i, methionine
complex; i-------A, free trans-dach; a----- • ___ a> monoaquamono¬
chloro complex.    B:    0 --------0, d, peak; • •  •  •   • I, d2 peak;
i — . — a, e+f peak minus the monoaquamonochloro complex.
55
when the platinum was labelled instead of the trans-dach
ligand. A 10 mg/kg [-^^^^Pt] tetraplatin dose was used due to
the limited amount of [^^^"^Pt] available. The [^^^"'Pt]
tetraplatin pharmacokinetics (Figure 7) were found to be
similar to the pharmacokinetics of the ["^H] tetraplatin at 12
mg/kg (Figure 1). The curve for the protein-bound platinum was
the only one that differed but it was not possible to determine
whether or not that was a significant deviation based on a
single experiment. It is interesting to note that the free
platinum was as persistent m the plasma whether a [ H-dach] or
|-195mp^-j label was used (Figures 1 and 7) . This suggests that
the bulky platinum biotransformation products formed by
displacement of the trans-dach carrier ligand are as persistent
as the lower molecular weight trans-dach.
It was apparent from the reverse phase profiles of the
^195mp^j tetraplatin experiment (Figure 8) that most of the
biotransformation products were eluting in the same positions
as the [ H] tetraplatin (Figure 2). Given that these data were
from one experiment, the profiles for peaks a, b^^, b2, d^^, e+f
and g were remarkably similar between the [ H] and [-^^^^Pt]
tetraplatin. The only qualitative difference was the presence a
of 40-41 min peak (peak h) with the [-^^^"'Pt] tetraplatin. This
peak probably represents a tetraplatin biotransformation
product in which the trans-dach carrier ligand has been
displaced.
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Figure 7. [  Pt] Tetraplatin Pharmacokinetics in Fischer 344 Male Rats.
[195mp^-] jetraplatin (10 mg/kg) was injected iv into a rat
at time 0. Plasma samples were obtained at 3.5 min, 7.5 min,
15 min, 30 min, 1 hr, 2 hr, and 3 hr and analyzed as described
in Materials and Methods. Platinum concentrations were
determined based on the specific activity of the [^^^""Pt]
tetraplatin (27.1 mCi/mmole) allowing for decay (t^ /g °
4.02 day). 7A, total platinum biotransformation products;
7B, free platinum biotransformation products; 7C, protein
bound platinum biotransformation products; 7D, percentage of
platinum biotransformation products which are protein bound.
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Figure 8. Reverse Phase Profiles of [^^Smpt] Tetraplatin Biotransforma¬
tion Products. Tetraplatin (10 mg/kg) was injected iv into
a Fischer 344 rat. Filtered plasma samples were analyzed by
HPLC as described in Materials and Methods. 8A, 7.5 min;
8B, 15 min; 8C, 30 min; 80. 1 hr; 8E, 2 hr; 8F. (0 -----0).
Pt(II)(methionine)2(trans-dach) standard; (a-----i). Pt(II)
(DDTC), standard. Both standards prepared as described in
Materials and Methods.
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Peaks e+f and g from the [195mPt] tetraplatin experiment
were further characterized by cation exchange HPLC at pH 4.0
(Figure 9). The e+f peak at 7.5 min was qualitatively identical
on cation exchange HPLC to the corresponding e+f peak from a
rat treated with [ H] tetraplatin (Figures 9A and 9B). A 2-hr
sample for the e+f peak was also compared to its corresponding
peak with [-^H] tetraplatin (Figures 9C and 9D) . Again, the
major peak was identical. Several smaller peaks were observed
in the [•^H] labeled sample. The peak at 31 min probably
represents free trans-dach from overlap of peak g. Considering
the small number of the counts in that sample, it is not clear
whether the other peaks are significant. When comparing the g
peaks from the [-^H] and [ ͣ' ͣ^^"'pt] tetraplatin experiments
(Figures 9E and 9F), it can be seen that the cation exchange
profiles at pH 4.0 are different. This unambiguously confirms
the presence of the free trans-dach in the 35 min peak of the
[ ͣ^H] tetraplatin-treated animals and suggests that a
tetraplatin biotransformation product is coeluting with the
free trans-dach compound on reverse phase HPLC.
Discussion
These data indicate that the administration of tetraplatin
to rats resulted in the formation of 4 to 9 biotransformation
products over a 3-hr period (Figure 2). Included in this group
of compounds are free trans-dach, a monoaquamonochloro species,
a mixture of methionine-platinum complexes, PtCl2(trans-dach)
and a nuitiber of unidentified compounds (Table 2 and Figure 8) .
The chromatographic profiles of the tetraplatin
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Figure 9.    Comparison of Cation Exchange Profiles of Reverse Phase Peaks e+f
and g from ['^H] and [^^^"pt] Tetraplatin-Treated Rats.    Cation
exchange HPLC was used to characterize peaks e+f and g from
Figs. 2 and 8.    Cation exchange HPLC was performed at pH 4.0 as
described in Materials and Methods.    9A, [ H] tetraplatin, 7.5 min,
peak e+f from Fig.  2A; 9B, [^^^"pt] tetraplatin, 7.5 min, peak e+f
from Fig. 8A; 9C, [ H] tetraplatin, 3 hr, peak e+f from Fig. 2F;
90, [^^^""Pt] tetraplatin, 2 hr,. peak e+f from Fig. 8E; 9E, [^H]
tetraplatin, 2 hr, peak g from Fig. 2E; 9F, [^^^""pt] tetraplatin,
2 hr, peak g from Fig. 8E.
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biotransformation products were similar to those found
intracellularly in L1210 cells by Mauldin et al. (1988). In
terms of platinum pharmacokinetics, tetraplatin became quickly
protein bound, with the binding plateauing at 2-3 hr (Figure
IC). Others have also reported that tetraplatin becomes rapidly
protein bound (Rahman et al., 1988; Hegedus et al., 1987).
DDTC administration at 0.5 hr after tetraplatin injection
had a profound effect both on platinum pharmacokinetics and
biotransformation products (Figures 1 and 3). The platinum
pharmacokinetic experiments indicated that the amounts of .
total, free and protein-bound platinum were altered by DDTC
administration (Figure 1). It appears from this data that DDTC
is reacting with platinum from the plasma proteins. Hegedus et
al. (1987) have demonstrated that DDTC can displace cisplatin
that is bound to human plasma proteins in vitro. Another
possible explanation for the increase in free platinum could be
the interaction of DDTC with intracellular pools of tetraplatin
biotransformation products. Such a hypothesis can be neither
confirmed nor excluded by these data.
These data indicate that some tetraplatin
biotransformation products are altered by DDTC administration
while others are not affected (Figures 2 and 3 and Table 2).
The only two compounds to increase after DDTC administration
were the free trans-dach and peak h. The data show
unambiguously that the free trans-dach comprises the majority
of the [-^H] labeled biotransformation products after DDTC
administration (Figures 2 and 9). In fact, the free trans-dach
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increased 4-fold above the levels seen for animals treated with
tetraplatin alone (Table 2). These results strongly suggest the
formation of a bis, bidentate platinum(II)-DDTC complex with
the resultant displacement of the trans-dach carrier ligand.
Of the other biotransformation products, the methionine-
platinum complexes, PtCl2(trans-dach), the monoaquamonochloro
species and peak d2 (unidentified) were found to decrease in
concentration after DDTC administration (Table 2)• Dedon and
Borch (1987) have suggested that the direct reaction of
cisplatin and DDTC at maximum concentrations in the blood would
occur with a t-j^/2 of approximately 190 min. These results are
in disagreement with their hypothesis that platinum can not
interact with DDTC at physiological concentrations found in the
blood. The disappearance of the methionine-platinum complexes
is in agreement with a previous study that suggests DDTC can
readily displace methionine from methionine-platinum complexes
(Andrews it al., 1984). Both the monoaquamonochloro species and
PtCl2(trans-dach) decrease by about one-half after DDTC
administration. This is not surprising based on the reactivity
of these two compounds (Mauldin et al., 1988; Daley-Yates and
McBrien, 1984). All of the other tetraplatin biotransformation
products remained fairly constant after DDTC administration
(Table 2).
The mechanism by which DDTC protects against cisplatin-
induced toxicity was not clearly defined. Borch and coworkers
have postulated several mechanisms including reversal of the
platinum inactivation of renal enzymes (Dedon and Borch, 1987)
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or possible enhancement of growth in the pluripotent bone
marrow stem cells (Gringeri et al., 1988). Based on these data,
there appears to be a number of ways by which DDTC could be
exerting its protective effect. The most likely mechanism is
the inactivation of cytotoxic biotransformation products in the
plasma by DDTC. Such a mechanism can be supported by the
decrease in the PtClj(trans-dach) and the monoaquamonochloro
species (Table 1 and Figure 8), both which are highly reactive
compounds. This same mechanism of action (inactivation of
cytotoxic biotransformation products) could also be occurring
intracellularly in the target organs. Two other mechanisms of
action could also be postulated. One mechanism involves the
chelating of platinum from plasma proteins (Figure ID). The
protein bound platinum may be responsible for the toxicities
associated with tetraplatin by a slow release of the platinum
from the plasma proteins. This could also explain why
tetraplatin toxicity is most severe on day 5 after tetraplatin
administration. Another possible mechanism could be increased
biliary excretion of platinum as a result of DDTC
administration. Basinger et al. (1989) have reported that
biliary excretion of cisplatin can be increased 3 0-fold by the
administration of DDTC prior to cisplatin. They suggest that
the renal protection afforded by DDTC is the result of a shift
in platinum excretion to the bile. As a result of the
significant decrease in total platinum levels after DDTC
administration (Figure lA), the same type of mechanism could be
hypothesized from this investigation.
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